NCT07094932View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 3, 2025

Primary Completion Date

December 13, 2025

Study Completion Date

December 13, 2025

Conditions
Healthy Adult Participants
Interventions
DRUG

TBD09

TBD09 will be administered orally

DRUG

Placebo

Placebo will be administered orally

Trial Locations (1)

68502

RECRUITING

Celerion, Lincoln

Sponsors
All Listed Sponsors
lead

Gates Medical Research Institute

OTHER